Researchers have found that responses to PD-1 inhibitor treatment in patients with advanced melanoma may depend on whether they had received previous treatment with CTLA-4 inhibitors, according to a new study published by Campbell et al in Cancer Cell. Researchers conducted an analysis of seven data sets generated over the past decade—which included tumor biopsy results from over 500 patients with melanoma—and assembled and harmonized a large set of tumor and clinical data in order to identify key factors associated with treatment responses. They found that prior treatment with CTLA-4 inhibitors was associated with differences in genomic, individual gene, and gene signatures among patients who were then treated with—and responded to—PD-1 inhibitors.
May 24, 2023